ANNUAL IND SAFETY SUMMARIES ARE "DESIRABLE" BUT SEMI-ANNUAL REPORTS ARE UNJUSTIFIED FOR NEW ADR REPORTING REGS: PhRMA ASKS FOR DELAY IN ISSUING REGS
The addition of safety summaries to IND annual reports would be useful, but semi-annual safety reports are unnecessary, the Pharmaceutical Research & Manufacturers of America maintains in recent comments on FDA recommendations for changes in adverse event reporting. The comments also cover the conduct of early clinical trials as described in FDA's task force report on Lilly/Oclassen's FIAU (fialuridine) toxicity released in November 1993 ("The Pink Sheet" Nov. 22, 1993, p. 15).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth